Stocktoria
LB PHARMACEUTICALS INC LBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-09-11
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Net income | -$25.2M | -$63.1M |
| Operating cash flow | -$35.2M | -$53.1M |
| Free cash flow | -$35.3M | -$53.8M |
| Total assets | $312.9M | $33.5M |
| Total liabilities | $11.6M | $13.8M |
| Shareholders' equity | $301.3M | -$94.6M |
| Ratios | ||
| Return on assets | -8.1% | -188.2% |
| Return on equity | -8.4% | 66.7% |
| Current ratio | 41.44 | 3.56 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001691082 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.